The authors discuss the case of a 22 year-old patient treated for lepromatous leprosy who developed acute hepatitis 2 years after beginning polychemotherapy associating thalidomide, rifampin, ethionamide and clofazimine. Besides the ethionamide, there was no hepato-toxic factor and the hepatic anomalies quickly disappeared upon termination of treatment with this product. This again draws attention to the hepato-toxicity of ethionamide.
BT - Annales de gastroenterologie et d'hepatologie C1 - http://www.ncbi.nlm.nih.gov/pubmed/3729286?dopt=Abstract DA - 1986 May-Jun IS - 3 J2 - Ann Gastroenterol Hepatol (Paris) LA - fre N2 -The authors discuss the case of a 22 year-old patient treated for lepromatous leprosy who developed acute hepatitis 2 years after beginning polychemotherapy associating thalidomide, rifampin, ethionamide and clofazimine. Besides the ethionamide, there was no hepato-toxic factor and the hepatic anomalies quickly disappeared upon termination of treatment with this product. This again draws attention to the hepato-toxicity of ethionamide.
PY - 1986 SP - 129 EP - 30 T2 - Annales de gastroenterologie et d'hepatologie TI - [The hepatotoxicity of ethionamide remains a topical subject. Apropos of a case of acute hepatitis]. VL - 22 SN - 0066-2070 ER -